Efficacy and tolerability of pregabalin in patients with neuropathic pain. Observational study under clinical practice conditions;Pregabalin bei patienten mit neuropathischen schmerzen. Wirksamkeit und verträglichkeit unter praxisbedingungen

MMW-Fortschritte der Medizin

Volumn 149, Issue 10 SUPPL., 2007, Pages 1-8

  Mallison, R ^a   Tilke, C ^a   Brasser, M ^a   Pittrow, David ^b,c  

^a PFIZER INC   (United States)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Efficacy; Neuropathic pain; Onset of action; Practice conditions; Pregabalin; Tolerability

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; PREGABALIN;

ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHIC PAIN; PARESTHESIA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRESCRIPTION; SLEEP DISORDER; TRIGEMINUS NEURALGIA;

EID: 34247216709     PISSN: 14383276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. In: Merskey, H., Bogduk, N. (eds.). 2nd ed. Task Force on Taxonomy of the IASP. Seattle: IASP Press, 1994.
2. Anonymus: Empfehlungen zur Planung und Durchführung von Anwendungsbeobachtungen. Bundesanzeiger 229(1998);16884.
3. Backonja, M., Glanzman, R. L.: Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin. Ther. 25 (2003), 81-104.
4. Baron, R., Binder, A.: Wie neuropathisch ist die Lumboischialgie? Das Mixed-pain-Konzept. Orthopäde 33 (2004), 568-575.
5. Bian, F., Li, Z., Offord, J., et al.: Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 1075 (2006), 68-80.
6. Bowsher, D.: The management of postherpetic neuralgia. Postgrad. Med. J. 73 (1997), 623-629.
7. Brodie, M. J., Wilson, E. A., Wesche, D. L., et al.: Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 46 (2005), 1407-1413.
8. Carter, G. T., Jensen, M. P., Galer, B. S., et al.: Neuropathic pain in Charcot-Marie-Tooth disease. Arch. Phys. Med. Rehabil. 79 (1998), 1560-1564.
9. Chong, M., Bajwa, Z. H.: Diagnosis and treatment of neuropathic pain. J. Pain Symptom Manage. 25 (2003), S4-11.
10. Choo, P. W., Galil, K., Donahue, J. G., Walker, A. M., Spiegelman, D., Platt, R.: Risk factors for postherpetic neuralgia. Arch. Intern. Med. 157 (1997), 1217-1224.
11. Concato, J., Shah, N., Horwitz, R. I.: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342 (2000), 1887-1892.
12. Deyo, R. A., Weinstein, J. N.: Low back pain. N. Engl. J. Med. 344 (2001), 363-370.
13. Diop, L., Raymond, F., Fargeau, H., Petoux, F., Chovet, M., Doherty, A. M.: Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J. Pharmacol. Exp. Ther. 302 (2002), 1013-1022.
14. Doig, G. S., Simpson, F.: Randomization and allocation concealment: a practical guide for researchers. J. Crit. Care 20 (2005), 187-193.
15. Dworkin, R., Sharma, U., Stacey, B., Chambers, R., Siffert, J.: Long-term treatment of neuropathic pain and fibromyalgia syndrome with pregabalin in treatment-refractory patients [abstract]. 24. Annual Meeting of the American Pain Society. Boston, USA, 30.3.-2.4.2005.
16. Dworkin, R. H., Corbin, A. E., Young, J. P., Jr., et al.: Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60 (2003), 1274-1283.
17. Frampton, J. E., Foster, R. H.: Pregabalin: in the treatment of postherpetic neuralgia. Drugs 65 (2005), 111-120.
18. Frampton, J. E., Scott, L. J.: Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs 64 (2004), 2813-2821.
19. Freynhagen, R., Baron, R., Tölle, T., et al.: Screening of neuropathic pain components in patients with chronic back pain associated with nerve root compression: a prospective observational pilot study (MIPORT). Curr. Med. Res. Opin. 22 (2006), 529-537.
20. Freynhagen, R., Busche, P., Conrad, C., Balkenohl, M.: Wirksamkeit und Wirkungsbeginn von Pregabalin bei Patienten mit neuropathischen Schmerzen. Schmerz 4 (2006), 293-299.
21. Freynhagen, R., Strojek, K., Griesing, T., Whalen, E., Balkenohl, M.: Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115 (2005), 254-263.
22. Galer, B., Gianas, A., Jensen, M. P.: Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res. Clin. Pract. 47 (2000), 123-128.
23. Jensen, T. S., Gottrup, H., Sindrup, S. H., Bach, F. W.: The clinical picture of neuropathic pain. Eur. J. Pharmacol. 429 (2001), 1-11.
24. Kost, R. G., Straus, S. E.: Postherpetic neuralgia - pathogenesis, treatment, and prevention. N. Engl. J. Med. 335 (1996), 32-42.
25. Kuehn, B. M.: Pain studies illuminate the placebo effect. J. Am. Med. Assoc. 294 (2005), 1750-1751.
26. Lamberg, L.: Sleep disorders, often unrecognized, complicate many physical illnesses. J. Am. Med. Assoc. 284 (2000), 2173-2175.
27. Lauria-Horner, B., Pohl, R.: Pregabalin: a new anxiolytic. Expert Opin. Investig. Drugs 12 (2003), 663-672.
28. Lesser, H., Sharma, U., LaMoreaux, L., Poole, R. M.: Pregabalin relieves symptoms of painfuldiabetic neuropathy: a randomized controlled trial. Neurology 63 (2004), 2104-2110.
29. Max, B.: Antidepressants as analgesics. In: Fields, H. L., Liebeskind, J. C.: Progress in brain research and management. 1. ed. IASP, Seattle, USA, 1994, pp. 229-246.
30. Meister, W.: Die Anwendungsbeobachtung-eine BeobachtungderAnwendung. Dtsch. Med. Wochenschr. 128 (2003), 859-862.
31. Meyer-Rosberg, K., Kvarnstrom, A., Kinnman, E., Gordh, T., Nordfors, L. O., Kristofferson, A.: Peripheral neuropathic pain - a multidimensional burden for patients. Eur. J. Pain 5 (2001), 379-389.
32. Namaka, M., Gramlich, C. R., Ruhlen, D., Melanson, M., Sutton, I., Major, J.: A treatment algorithm for neuropathic pain. Clin. Ther. 26 (2004), 951-979.
33. Pfizer: Data on file.
34. Quattrini, C., Tesfaye, S.: Understanding the impact of painful diabetic neuropathy. Diab. Metab. Res. Rev. 19 (Suppl. 1) (2003), S2-8.
35. Richter, R., Portenoy, R., Sharma, U., LaMoreaux, L., Bockbrader, H., Knapp, L.: Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J. Pain. 6 (2005), 253-260.
36. Rosenstock, J., Tuchman, M., LaMoreaux, L., Sharma, U.: Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110 (2004), 628-638.
37. Sabatowski, R., Galvez, R., Cherry, D. A., et al.: Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109 (2004), 26-35.
38. Schmader, K.: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain 18 (2002), 350-354.
39. Wallin, J., Cui, J. G., Yakhnitsa, V., Schechtmann, G., Meyerson, B. A., Linderoth, B.: Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy. Eur. J. Pain 6 (2002), 261-272.
40. Woolf, C., Mannion, R. J.: Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353 (1999), 1959-1964.